Get the app
US › Healthcare

Korro Bio, Inc. (KRRO)

US · Healthcare · Biotechnology

$8.49-8.81%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-18.9M
EPS
$-1.07
EPS estimate
$-1.54

EPS came in at -1.07 against a street estimate of -1.54 — a beat of 30.5%.

Key statistics

Market cap
$149.6M
Forward P/E
0.0
P/B
1.40
Book value
$7.02
EPS (TTM)
$-9.88
52-week high
$55.89
52-week low
$5.20
50-day MA
$11.90
200-day MA
$11.75
Beta
2.36

Analyst view

Analysts rate Korro Bio, Inc. a strong buy (10 buy, 1 hold, 0 sell out of 11) with an average price target of $20.20.

Shareholding

Insiders
0.89%
Institutions
105.23%

Largest institutional holders

FundStake
Lynx1 Capital Management, LP10.45%
Nantahala Capital Management, LLC8.96%
NEA Management Company, LLC8.81%
VR Adviser, LLC6.86%
Atlas Venture Life Science Advisors, LLC6.54%
Balyasny Asset Management LLC6.46%
BlackRock Inc5.55%
Affinity Asset Advisors, LLC4.80%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Korro Bio, Inc. — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.